What to Do When Semaglutide Stops Working

The biggest misconception: a plateau means semaglutide has stopped working permanently

When the scales stop moving, the instinct is to conclude the medicine has lost its effect. That is rarely accurate. Semaglutide continues to act on GLP-1 receptors throughout treatment, slowing gastric emptying and dampening appetite signals. What changes is the body's energy balance. As you lose weight, your basal metabolic rate falls (you simply need fewer calories to sustain a lighter body) and that narrowing gap between intake and expenditure slows measurable progress on the scales. This is sometimes called metabolic adaptation, and it happens with every form of sustained weight loss, not just GLP-1 treatment.

There is also a behavioural layer. Early in treatment, reduced appetite makes dietary changes feel almost effortless. Over months, habits settle, portion sizes creep up, and the novelty of monitoring what you eat fades. The medicine has not changed; the context around it has. The reasons semaglutide appears to stop working are almost always addressable once you identify which factor is driving the stall.

One practical detail many people find useful: taking your weekly injection on the same day and storing your pen correctly (refrigerated between 2°C and 8°C when not in use, such as in the fridge door) helps ensure each dose is delivered as the prescriber intended, ruling out storage or missed-dose issues as a cause of reduced effect.

What your prescriber can actually do about it

Once it is clear that a genuine plateau has set in rather than a short-term slowdown, there are several evidence-based routes a prescriber may consider. The first is reviewing whether you are on the highest dose your body tolerates. Wegovy's licensed maintenance dose is 2.4mg weekly, but some patients plateau at a lower dose without having reached that ceiling. A titration review is often the starting point. The MHRA approved a higher 7.2mg semaglutide dose in January 2026, which clinical trials found produced around 20.7% average weight loss over 72 weeks, a meaningful step up from 2.4mg results for eligible patients.

Beyond dose, a prescriber will look at whether the lifestyle support running alongside treatment is adequate. Protein intake, resistance activity, sleep, and stress all affect body composition and the rate of weight loss. GLP-1 medicines work best when those foundations are solid, and a clinical review is a good opportunity to assess them honestly.

If semaglutide genuinely appears to have reached its ceiling even at maximum tolerated dose, switching medicines is a legitimate clinical option. Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist (the only medicine of its kind licensed in the UK for weight management) and in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine (2025), it produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. Cost is a factor many people weigh up at this decision point, and a prescriber can help you look at this alongside clinical suitability rather than in isolation.

When stopping semaglutide might be the right answer

NICE guidance for semaglutide (TA875) recommends considering stopping if less than 5% weight loss has been achieved after six months on the maintenance dose. That is a specific clinical threshold, not a general rule of thumb. It exists because, for a small proportion of people, the medicine's effect on appetite is genuinely limited, and continuing indefinitely without meaningful progress is not in the patient's interest. Whether Wegovy has truly stopped working for you is something a prescriber is best placed to assess, with access to your full weight history and medical background, not a conclusion to draw from a few weeks of slower progress.

It is also worth knowing that weight typically returns when GLP-1 treatment stops, because the underlying biological drivers of appetite and energy regulation remain. That is not a reason to stay on a medicine that is not working; it is context for having a full conversation with your prescriber about long-term plans, including whether an alternative such as continuing on a higher semaglutide dose or transitioning to tirzepatide makes clinical sense for you.

If you are uncertain whether your current treatment is still doing its job, the steps to take if Wegovy stops working are worth reviewing before any decision. And if you want a clinical opinion rather than general information, our prescribers review consultations the same day, a real clinician reads your answers, not a queue for software. You can read more about our clinical team on the clinical team page.

The timeline for when Wegovy starts working is useful context too, understanding how the medicine behaves across months can help distinguish a genuine plateau from a normal period of slower progress early in treatment.

The NHS medicines page for semaglutide covers the full side-effect profile and what to do if you have concerns, and NICE's appraisal of semaglutide for weight management (TA875) sets out the clinical criteria used to evaluate whether treatment is working and when to review continuing. Both are useful reading before a prescriber appointment.

If you are ready to discuss your options with a clinical team, you can start your free consultation and receive a same-day review from a GPhC-registered prescriber.